GENEVA (Reuters) - A World Health Organization official on Tuesday said that the decision by AstraZeneca to pause global trials of its experimental coronavirus vaccine after an unexplained illness showed the firm was prioritising safety.
"This is what we want to see with trials, it is a well-run trial. Safety is always critical, it is crucial and they have looked at that in an appropriate manner," Margaret Harris told journalists in Geneva.
Asked to react to experimental COVID-19 vaccine use in China and Russia, she said: "The WHO would like to see vaccines go head to head so we can have clear information and to see these results against each other."
(Reporting by Emma Farge, editing by Louise Heavens)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)